Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin.

Haas, B; Eckstein, N; Pfeifer, V; Mayer, P; Hass, M D S

Haas, B; Eckstein, N; Pfeifer, V; Mayer, P; Hass, M D S.

Afiliação

Haas B; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Eckstein N; 1] Federal Institute for Drugs and Medical Devices, Bonn, Germany [2] Applied Pharmacy, University of Applied Sciences Kaiserslautern, Campus Pirmasens, Carl-Schurz-Str. 10-16, Pirmasens, Germany.
Pfeifer V; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Mayer P; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Hass MD; Federal Institute for Drugs and Medical Devices, Bonn, Germany.

Nutr Diabetes ; 4: e143, 2014 Nov 03.

Article em En | MEDLINE | ID: mdl-25365416

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Nutr Diabetes Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google